Despite being influenced by factors such as individual patient variation and disease staging, clinical trials of PD-1/PD-L1 monotherapy or combination therapy in relapsed or refractory DLBCL patients have made substantial strides [15, 16]. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.